<\/p>\n
Lipid-lowering, cardiovascular and anti-inflammatory effects of \u00abLetium\u00bb in patients with hypertension.<\/strong><\/p>\n Prof. M.N. Kochueva, prof. A.N. Korzh, PHD G.I. Kochuev, ass. V.A. Gavriluk, ass. O.A. Plehova. Kharkiv Medical Academy of Postgraduate Education, Kharkiv National Medical University.<\/strong><\/em><\/p>\n This paper studied the dynamics of the lipid spectrum of blood and functional state of the endothelium of blood C-reactive protein (CRP) in patients with hypertension stage 1-2, which were additional factors of cardiovascular risk, under the influence of adjuvant therapy with the use of the drug Letium. 12-week therapy with the inclusion of Letium was accompanied by a statistically significant reduction in plasma total cholesterol, total TG, LDL cholesterol, atherogenic factor and increased levels of anti atherogenic HDL cholesterol.<\/p>\n Key Words:<\/strong> hypertension, C-reactive protein, lipid lowering therapy, endothelium vasodilatation.<\/p>\nKochueva MN, Korzh AN, Kochuev GI, Gavriluk VA, Plehova OA. [Lipid-lowering, cardiovascular and anti-inflammatory effects of \u00abLetium\u00bb in patients with hypertension]. Shidnoevr. z. vnutr. simejnoi med. 2014;1:78-85. Russian.<\/span><\/h5>\n
http:\/\/dx.doi.org\/10.15407\/internalmed2014.01.078<\/a><\/span><\/h5>\n
\n\n
\n 1. Kovalenko VM, Kornatskij VM, authors; Kovalenko VM, editor. Analitychno-statystychnyi posibnyk [Analitical and statistical tutorial]. K.: Derzhavna ustanova \u00abNNTs Instytut kardiolohii imeni akademika M.D. Strazheska\u00bb. 2013; 239. Ukrainian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 2. Pospelov DL. Arterialnaia gipertenziia i serdechno-sosudistyi risk v prakticheskoi deiatelnosti vracha [Arterial hypertension and cardiovascular risk in doctor’s practice]. Ukra\u0457nskii medichnii chasopis. 2013; 2 (94): 6\u20148. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 3. Horbas IM, Barna OM, Sakalosh VI. Otsinka poshyrenosti ta kontroliu faktoriv ryzyku sertsevo- sudynnykh zakhvoriuvan sered naselennia ta likariv. [Evaluation of widespread and control of risk factors of cardiovascular diseases among population and doctors]. Liky Ukrainy. 2010; (1): 4\u20149. Ukrainian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 4. European society of hypertension. European society of cardiology. Klinichni rekomendatsii z arterialnoi hipertenzii Yevropeiskoho tovarystva hipertenzii (ESH) ta tovarystva kardiolohiv (ESC) 2013 roku [Clinical recommendations for arterial hypertension]. Arterialna hipertenziia. 2013; 4 (30): 160. Ukrainian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 5. Sirenko YM, author. Arterialna hipertenziia ta suputnia patolohiia. [Arterial hypertension and comorbidities]. Donetsk: Vydavets Zaslavskyi O.I. 2010; 384. Ukrainian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 6. Molchanova OA. Arterialnaia gipertenziia pri ozhirenii [Arterial hypertension in obesity]. Vrach. 2006; 3: 30\u201433. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 7. Rabmouni K, Correia ML, Haynes WG. [Obesity \u2014 associated Hypertension. New insights into mechanisms]. Hypertension. 2005; (45): 9\u201414. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 8. Thomas F, Bean K, Pannier B. [Cardiovascular Mortality in Overweight Subiects. The Key Role of Associated Risk Factor]. Hypertension. 2005; (46): 654\u2014663. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 9. Guize L, Thomas F, Pannier B. [All-Cause Mortality Associated With Specific Combinations of the Metabolic Syndrome According to Recent Definitions]. Diabetes Care. 2007; 30: 2381\u20142387. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 10. Narkiewicz K. [Obesity and hypertension \u2014 the issue is more complex than we thought] Nephrol Dial Transplant. 2006; 21: 264\u2014267. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 11. Thomas F, Bean K, Pannier B. [Cardiovascular Mortality in Overweight Subjects.The Key Role of Associated Risk Factors]. Hypertension. 2005; 46: 654\u2014663. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 12. Neaton ID, Wentworth D. [Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group] Arch. Intern. Med. 1992; 152 (1): 56-64. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 13. Thanassoulis GI, Lyass A, Beniamin EI, Larson MG, Vita IA, Levy D, Hamburg NM, Widlansky ME, O’Donnell CI, Mitchell GF, Vasan RS. [Relations of exercise blood pressure response to cardiovascular risk factors and vascular function in the Framingham Heart Study] Circulation. 2012; 125(23):2836-2843. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 14. Barter P, Gotto AM, Rosa LI [HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events] The New England iournal of medicine. 2007; 357 (13): 1301\u20141310. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 15. Bezrodnaia LV. Arterialnaia gipertenziia i dislipidemiia. [Arterial hypertension and dyslipidaemia] Zdorovia Ukra\u0457ni.2007; 8: 28\u201429. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 16. Pavlova OS. Sovremennye vozmozhnosti effektivnoi serdechno-sosudistoi profilaktiki u patsientov s arterialnoi gipertenziei i dislipidemiei. [Moderm opportunities of effective cardiovascular prevention in patients with arterial hypertension and dyslipidaemia]. Meditsinskie novosti. 2012; (1): 62\u201468. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 17. Deivid DM, Sergio F, Makrae FL. Sovremennye perspektivy primeneniia statinov [Modern perspective of statin usage] Mezhdunarodnyi meditsinskii zhurnal. 2000; (6): 516\u2014521. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 18. Sergienko IV. Istoriia poiavleniia statinov. [History of statins appearance]. Ateroskleroz i dislipidemii. 2011; 1: 57-66. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 19. Endo A, Kuroda M, Tanzawa \u041a. [Competitive inhibition of 3-hydroxy-3-methylglutaryl \u0441oenzyme A reductase by ML-236 and \u041cL-236\u0412, fungal metabolites having hypocholesterolemic activity]. FEBS Lett.1976; 72: 323\u2014326. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 20. Endo A, \u041auroda M, Tsuiita Y. [ML-236A, \u041cL-236\u0412 and \u041cL-236\u0421, new inhibitors of cholesterogenesis produced by P.citrinum]. I. Antibiot.1976; 29(12): 1346 – 1348. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 21. Endo A, Komagata D, Shimada H, Monacolin M. [A new inhibitor of cholesterol biosynthesis]. Ibid. 1986; 39 (12): 1670\u20141674. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 19. Trutko SM, Shcherbakova VA, Ivanova IV. Vzaimosviaz putei biosinteza izoprenoidov i katabolizma istochnika ugleroda u anaerobnykh i fakultativno anaerobnykh bakterii. [Correlation of pathways of biosynthesis of isoprenoids and catabolism of carbon sourse in anaerobic and facultative anaerobic bacteria]. Mikrobiologiia. 2008; 77(3): 303\u2014310. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 20. Zuzuk BM, Kutsik RV, Tomchuk I. Ginkgo biloba (analiticheskii obzor). [Ginkgo biloba (analytical review)]. Provizor. 2001; (19): 34. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 21. Iurev DV, Eller KI, Arzamastsev AP. Analiz flavonolglikozidov v preparatakh i BAD na osnove ginkgo biloba. [Analysis of phlavonolglycozides in preparations and BAD on basis of ginkgo biloba]. Farmatsiia. 2003; (2): 7. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 22. Kuznetsova SM, Glazovskaia II. Primenenie tanakana dlia neirofarmakologicheskoi reabilitatsii bolnykh, perenesshikh insult. [Use of tanakan for neuropharmacological rehabilitation of patients after stroke] In: [Tez. dokl materialy nauchno- prakticheskogo simpoziuma \u00abTanakan\u00bb]. Kiev.1997; 7. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 23. Bulaev VM. Klinicheskaia farmakologiia ekstrakta listev ginkgo biloba. [Clinical pharmacology of extract of leaves of ginkgo biloba]. Mediko-farmats. Vestnik. 1996; 8 (7): 33. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 24. Damulin IV, Zakharov VV, Elkin MN. Tanakan pri distsirkuliatornoi entsefalopatii. [Tanakan in neurovascular encephalopathy]. Klinich. Gerontologiia. 1996; (4): 51. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 25. Kleiinen I, Knipschild P [Ginkgo biloba] Lancet. 1992; 340 (7): 1136.<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 26. Balashova TS, Kubatiev AA. Vliianie tanakana na perekisne okislenie lipidov krovi i agregatsionnye svoistva trombotsitov u bolnykh insulinzavisimym sakharnym diabetom. [Influence of tanakan on peroxidation of blood lipids and aggregation properties of platelets. Terapevt. arkhiv.1998; 70 (12): 49. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 27. Celermaier DS, Sorensen KE, Bull C [Endotheliumdependent dilation in the systemic arteries of a symptomatic subiects relates to coronary risk factors and the interaction]. I. Am. Coll. Cardiol. 1994; 24: 1468\u20141474. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 28. Ivanova OV, Balakhonova TV, Soboleva GN, Atkov OI, Karpov IA. Sostoianie endoteliizavisimoi dilatatsii plechevoi arterii u bolnykh gipertonicheskoi bolezniu, otsenivaemoe s pomoshchiu ultrazvuka vysokogo razresheniia. [State of endotheliumdepedent dilatation of brachial artery in patients with arterial hypertension, evaluated by ultrasound of high resolution]. Kardiologia.1997; (7): 41\u201447. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 29. Ridker PM, Danielson E, Rifai N. [Blood pressure reduction, and C-reactive protein: primary report of theValMARC trial]. Hypertension. 2006; 48: 73\u201479. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 30. Ridker P, Glynn R, Hennekens C. [C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction]. Circulation. 1998; 97: 2007\u201411. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 31. Reziapova NK, Kriukov NN, Kiseleva GI, Bogdanova IA. Izmenenie faktora Villebranda pri AG. [Changes of Villebrand factor in AG]. In: Rossiiskii natsionalnyi kongress kardiologov. M. 2007; 162. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 32. Kramareva VN, Lugovskoi EV. Pokazateli svertyvaiushchei sistemy krovi i protivotromboticheskie mekhanizmy u bolnykh essentsialnoi arterialnoi gipertenziei. [Indexes of blood clotting system and antithrombotic mechanisms in patients with essential hypertension]. Ukr. Med. Chasopis. 2010; 77 (3): 32\u201437. Russian<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 33. Blann A. [Von Willebrand factor and the endothelium in vascular disease]. Br. I. Biomed. Sci.1993; 50(2): 125\u2014134. English<\/td>\n<\/tr>\n \n <\/td>\n<\/tr>\n \n 34. Balashova TS, Kubatiev AA. Vliianie tanakana na perekisne okislenie lipidov krovi i agregatsionnye svoistva trombotsitov u bolnykh insulinzavisimym sakharnym diabetom [Influence of tanakan on blood lipids peroxidation and aggregation properties of platelets in patients with insulin-dependent diabetes mellitus]. Terapevt. arkhiv.1998; 70(12): 49. Russian<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,15,27],"tags":[],"translation":{"provider":"WPGlobus","version":"2.12.2","language":"en","enabled_languages":["uk","en","ru"],"languages":{"uk":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false},"ru":{"title":true,"content":true,"excerpt":false}}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/440"}],"collection":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/comments?post=440"}],"version-history":[{"count":7,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/440\/revisions"}],"predecessor-version":[{"id":751,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/440\/revisions\/751"}],"wp:attachment":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/media?parent=440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/categories?post=440"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/tags?post=440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}